Phosphoramide compounds

Details Phosphoramide compounds Phosphoramide compounds

2007-12-04

2007-12-04

Shameem, Golam M. M. (Department: 1626)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Phosphorus containing other than solely as part of an...

C558S070000, C558S199000, C514S137000

Reexamination Certificate

active

10725191

ABSTRACT:
The invention provides a compound of formula I:wherein R1, Ra, Rb, Rc, and Rdhave any of the values defined in the specification, as well as pharmaceutical compositions comprising such compounds or salts. The compounds are useful for treating cancer in animals.

REFERENCES:
patent: 4908356 (1990-03-01), Borch et al.
patent: 5190929 (1993-03-01), Borch et al.
patent: 5233031 (1993-08-01), Borch et al.
patent: 5472956 (1995-12-01), Borch et al.
patent: 5659061 (1997-08-01), Glazier
patent: 6656926 (2003-12-01), Borch et al.
patent: 6903081 (2005-06-01), Borch et al.
patent: 0553673 (1993-01-01), None
patent: WO-89/11484 (1989-11-01), None
patent: WO-90/10636 (1990-09-01), None
patent: WO 93/06120 (1993-04-01), None
patent: WO-96/33198 (1996-10-01), None
patent: WO 01/74827 (2001-10-01), None
Flader, Carolee , et al., “Development of Novel Quinone Phosphorodiamidate Prodrugs Targeted to DT-Diaphorase”,J. Med. Chem., vol. 43, No. 16, (Aug. 10, 2000),3157-3167.
Workman, Paul , “Enzyme-Directed Bioreductive Drug Development Revisited: A commentary on recent progress and future prospects with emphasis on quinone anticancer agents and quinone metabolizing enzymes, particularly DT-diaphorase”,Oncol. Res., vol. 6, XP000946783, (1994),461-475.
“The Synthesis of O-Monosaccharldyl-Methoxycarbonyl-Phosphonamidaes by Arbuzov Reaction,” Chen et al., Chinese Chemical Letters, vol. 6, No. 1, pp. 23-26, 1995.
“Design and Synthesis of Lipophillic Phosphoramidate d4T-MP Prodrugs Expressing High Potancy Against HIV In Cell Culture: Structural Determinants forIn vitroActivity and OSAR,” Sleeiqul, et al., J. Med. Chem.1999, 42, 4122-4128.
“Phosphoramidates as Potent Prodrugs of Anti-HIV Nucleotides: Studies In the Amino Region,” McGuigan et al., Antiviral Chemistry & Chemotherapy (1996) 7(1), 31-36.
“Design and Synthesis of Noval Nucleotide Prodrugs,” Meyers et al., American Association for Cancer Research 2000 (Abstract Proof Page), Abstract #100710, dated Dec. 2, 1999.
“Protein Tyrosine Kinases and Cancer,”Kollbaba et al., Biochimica et Biophysics Acta 1333 (1997) F217-F248.
“Receptor Protein-Tyrosine Kinases and Their signal Transduction Pathways,” van der Geer et al., Annu. Rev. Cell Biol., 1994, 10:251-337.
“Src Homology Region 2 Domains Direct Protein-Protein Interactions in Signal Transduction,” Moran et al., Proc. Natl. Acad. Sci. USA, vol. 87, Nov. 1990, pp. 8622-8626.
“Binding of SH2 Domains of Phospholipasa Cryl, GAP, and Src to Activated Growth Factor Receptors,” Anderson et al., Science, vol. 250, Nov. 16, 1990, 979-982.
“Oncogenes and Signal Transduction,” Cantley et al., Cell, vol. 64, Jan. 25, 1991, 281-302.
“Recognition and Specificity In Protein Tyrosine Kinase-Mediated Signalling,” Songyang et al., TIBS 20, Nov. 1995, 470-475.
“Targeting Signal Transduction in the Discovery of Antiproliferative Drugs,” Saltiel et al., Chemistry & Biology, 1996, vol. 3, No. 11, 887-893.
“Peptide Inhibitors of src SH3-SH2-Phosphoprotein Interactions,” Glimer et al., The Journal of Biological Chemistry, vol. 269, No. 50, Dec. 16, 1994, 31711-31719.
“Structure-Based Design of a Novel Series of Nonpeptide Ligands That Bind to the pp60srcSH2 Domain,” Lunney et al., J. Am. Chem. Soc. 1997, 119, 12471-12476.
“Design, Synthesis, and Cocrystal Structure of a Nonpeptide SrcSH2 Domain Ligand,” Plummer et al., J. Med. Chem. 1997, 40, 3719-3725.
“Inhibition of SH2 Domain/Phosphoprotein Association by a Nonhydrolyzable Phosphonopeptide,” Domchek et al., Biochemistry 1992, 31, 9865-9870.
“Nonhydrolyzable Phosphotyrosyl Mimetics for the Preparation of Phosphatase-resistant SH2 Domain Inhibitors,” Burke, Jr., et al., Biochemistry, 1994, 33, 6490-6494.
L-O-(2-Malonyl)tyrosine: A New Phosphyotyrosyl Mimetic for the Preparation of Src Homology 2 Domain Inhibitory Peptides, Ye et al., J. Med. Chem. 1995, 38, 4270-7275.
“Comformationally Constrained Phosphotyrosyl Mimetics Designed as Monomeric Src Homology 2 Domain Inhibitors,” Burke Jr., et al., J. Med. Chem. 1995, 38, 1386-1396.
“4′-O-[2-(2-Fluoromalonyl)]-L-Tyrosine: A Phosphotyrosyl Mimic for the Preparation of Signal Transduction Inhibitory Peptides,” Burke Jr., et al., J. Med. Chem. 1996, 39, 1021-1027.
“Phosphotyrosine-Containing Dipeptides as High-Affinity Ligands for the p56ICKSH2 Domain,” Llinas-Brunet et al., J. Med. Chem. 1999, 42, 722-729.
“Acquisition of High-Affinity, SH2-Targeted Ligands via a Spatially Focused Library,” Lee et al., J. Med. Chem. 1999, 42, 784-787.
“Ligands for the Tyrosine Kinase p56-ICK-SH2 Domain: Discovery of Potent Dipeptide Derivatives with Monocharged, Nonhydrolyzable Phosphate Replacements,” Beaulieu et al., J. Med. Chem. 1999, 42, 1757-1766.
“Synthesis and Biological Evaluation of 5-Fluoro-2′-Deoxyuridine Phosphoramidate Analogs,” Fries et al., J. Med. Chem., 1995, 38, 2672-2680.
“Synthesis and Biological Activity of Noval 5-Fluoro-2′-Deoxyuridine Phosphoramidate Prodrugs,” Meyers et al., J. Med. Chem., 2000, 43, 4313-4318.
“Synthesis and Evaluation of Nitroheterocyclic Phosphoramidates as Hypoxia-Selective Alkylating Agents,” Borch et al., J. Med. Chem., 2000, 43, 2258-2265.
Gibbs et al., Current Medicinal Chemistry, vol. 8, No. 12, Oct. 2001, pp. 1437-1465.
Borch et al., European Journal of Cancer. Supplement, Pergamon, Oxford, GB, vol. 2, No. 8, Sep. 2004, p. 176.
Weidong et al., American Chemical Society. Abstracts of Papers at the National Meeting, ACS, Washington, D.C., vol. 228, Part 1, Aug. 26, 2004, p. U930.

Affiliated with

Also associated with

Rating

Phosphoramide compounds does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Phosphoramide compounds, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Phosphoramide compounds will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3838031